Jounce Therapeutics Will Present New Data On Potential Predictive Biomarker From Vopratelimab ICONIC Trial At 2020 ASCO-SITC Conference Feb. 6-8

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from the vopratelimab

Benzinga · 12/19/2019 20:00

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from the vopratelimab ICONIC trial, on the association of a predictive RNA signature with the emergence of ICOS hi CD4 T cells and clinical outcomes, will be presented at a poster session at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting, being held February 6-8, 2020 in Orlando, Florida.

“We are pleased to present the new data that led to our selection of a predictive biomarker for our next vopratelimab trial. We believe patient selection strategies to identify patients more likely to respond to immuno-oncology therapies may better address unmet medical needs,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. “The potential predictive biomarker that we will present at ASCO-SITC is an RNA signature. In 2020, we plan to initiate the new Phase 2 predictive biomarker trial, which will study vopratelimab in combination with our investigational PD-1 inhibitor, JTX-4014, in RNA signature selected patients.”

 
Poster Presentation Details
   
Title:  Association of a predictive RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial
Author:  Timothy A. Yap, M.B.B.S., Ph.D., M.R.C.P., B.S., The University of Texas MD Anderson Cancer Center 
Session Title:  Poster Session A
Abstract Number:  14
Session Date and Time:  Thursday, February 6, 2020, 11:30 AM-1:00 PM and 6:00 PM-7:00 PM ET